Intensified Downstream Processing of Monoclonal Antibodies Using Membrane Technology

Area of Science:

• Biotechnology
• Chemical Engineering
• Process Intensification

Background:

• Advances in upstream monoclonal antibody (mAb) production necessitate parallel intensification of downstream processing.
• Traditional downstream methods face challenges in meeting the demands of increased mAb titers.
• The biopharmaceutical industry is shifting towards continuous and single-use manufacturing paradigms.

Purpose of the Study:

• To review recent developments in membrane-based technologies for monoclonal antibody bioprocessing.
• To highlight the role of membrane operations in integrating downstream processes.
• To focus on the progress towards intensified end-to-end bioprocesses.

Main Methods:

• Literature review of membrane-based unit operations in mAb downstream processing.
• Analysis of recent advancements and applications of membrane technologies.
• Evaluation of membrane technology's contribution to process integration and intensification.

Main Results:

• Membrane technologies offer operational flexibility and ease of implementation, aligning with industry needs.
• Integration of membrane unit operations is a key strategy for streamlining downstream processing.
• Significant progress has been made in applying membrane technologies for intensified mAb production.

Conclusions:

• Membrane technologies are essential for intensifying downstream processing of monoclonal antibodies.
• These technologies are vital for enabling continuous and single-use bioprocessing strategies.
• Further development and implementation of membrane-based solutions will drive the achievement of intensified end-to-end bioprocesses.